SAN MATEO, Calif., Oct. 30 Anthera Pharmaceuticals, Inc.,a privately held biopharmaceutical company developing anti-inflammatory drugsfor chronic and acute diseases, today announced that Donald J. Santel has beenappointed to Anthera's Board of Directors.
"Don's experience in transforming early biotech startups into commercialstage organizations will be of benefit as we expand our pipeline and moveA-002 into large scale Phase III clinical trials," said Paul F. Truex,President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "Hisstrategic and operational insights related to the challenges facingdevelopment stage companies will be invaluable as Anthera embarks on the nextphase of growth."
"We're pleased to have an individual of Don's caliber join our Board ofDirectors," said Lowell E. Sears? Chairman of Anthera's Board of Directors."We look forward to his contributions that will further shape strategicdirection and drive future growth."
Donald J. Santel has 25 years experience in thebiotechnology/biopharmaceutical and medical device industries. Most recently,he was Co-Founder and Chief Executive Officer at CoTherix, Inc., where helaunched Ventavis(R) Inhalation Solution and led the sale of the company toActelion Pharmaceuticals, Ltd. in January 2007. Prior to CoTherix, he servedas President and Chief Operating Officer of Reflow, and sold the company toFox Hollow (now EV3) and served as Vice President of Marketing andInternational Sales at Cardiac Pathways Corporation, a medical device companylater acquired by Boston Scientific. Mr. Santel began his career at Medtronic,Inc. Mr. Santel also serves on the board of Hyperion Therapeutics. He has aBSE from Purdue University and an MS in from the University of Minnesota.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held pharmaceutical developmentcompany committed to world-class development and commercialization ofpromising clinical products to address the unmet medical needs of patientswith life-threatening chronic and acute inflammatory diseases. In 2006,Anthera acquired worldwide rights (except Japan) to a series of clinical andpre-clinical compounds that inhibit the enzymatic activity of members of thephospholipase (PLA2) family -- a group of enzymes responsible for the releaseof arachidonic acid and subsequent production of leukotrienes? prostacyclinsand other mediators of inflammation. These highly potent compounds inhibitnovel? upstream steps in the inflammation cascade and have the potential toaddress a variety of diseases including: acute chest syndrome, acute lunginjury, acute respiratory distress syndrome, atherosclerosis, acute coronarysyndrome, chronic obstructive pulmonary disease and psoriasis. In order toefficiently commercialize this platform, Anthera has brought together a provenmanagement team with extensive experience in licensing, clinical research,development, and commercialization of anti-inflammatory products. For moreinformation please visit http://www.anthera.com.Contact: Anne Bowdidge (650) 218-6900 email@example.com
SOURCE Anthera Pharmaceuticals, Inc.